{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:46:59Z","timestamp":1740134819168,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,25]]},"DOI":"10.1182\/blood.2020005599","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T15:39:40Z","timestamp":1593099580000},"page":"2327-2328","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["CML: new tools to answer old questions"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-6592","authenticated-orcid":false,"given":"George","family":"Giotopoulos","sequence":"first","affiliation":[{"name":"Wellcome-MRC Cambridge Stem Cell Institute;"},{"name":"University of Cambridge;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J. P.","family":"Huntly","sequence":"first","affiliation":[{"name":"Wellcome-MRC Cambridge Stem Cell Institute;"},{"name":"University of Cambridge;"},{"name":"Cambridge University Hospitals"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"26","key":"2020062511393892100_B1","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2020062511393892100_B2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"10","key":"2020062511393892100_B3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020062511393892100_B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020062511393892100_B5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2020062511393892100_B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat Genet"},{"issue":"10","key":"2020062511393892100_B7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1084\/jem.20141661","article-title":"A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression","volume":"212","author":"Giotopoulos","year":"2015","journal-title":"J Exp Med"},{"issue":"8","key":"2020062511393892100_B8","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2020062511393892100_B9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"2020062511393892100_B10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2327\/1745426\/bloodbld2020005599c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2327\/1745426\/bloodbld2020005599c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T15:39:43Z","timestamp":1593099583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/26\/2327\/461045\/CML-new-tools-to-answer-old-questions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":10,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005599","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}